Biology of Blood and Marrow Transplantation · 2017 · 35 citations · 18 references
MedicineHematologyImmunologyImmunotherapyStem Cell TransplantationTransplant ImmunologyAllogeneic Stem Cell TransplantationDonor MatchingGraft-versus-host DiseaseHematopoietic Stem Cell Transplant PharmacotherapyAnti-thymocyte Globulin ConditioningCd4 T-cell DepletionImmune Cell DepletionImmunosuppressive Drug TherapyMatched Unrelated Donor TransplantationMismatched Donor TransplantationStem Cell DepletionUnrelated Donation
cells; P < .01) was observed in the ATG exposed cohort. No differences were noted in platelet engraftment. ATG exposed patients had significantly shorter time to neutrophil engraftment than the unexposed cohort (16 versus 19 days, respectively; P < .01). ATG exposed patients had significantly lower rates of GVHD than ATG unexposed patients (57% versus 79%; P = .01), with differences predominantly in rates of chronic GVHD (18% versus 44%, P < .01). At median follow-up of 28 (range, 3 to 69) and 25 (range, 2 to 73) months for survivors in ATG exposed and unexposed cohorts, respectively, no significant differences in overall survival (median overall survival not met for either cohort), relapse incidence (26% versus 29%, P = .73), or relapse-free survival (RFS) (not met in ATG exposed and 26 months in ATG unexposed, P = .22) were observed between groups. The ATG exposed cohort had significantly higher GVHD-free RFS (GRFS) with a 2-year GRFS of 23% versus 3% (P = .003). There were no significant differences between cohorts in proportion of patientswith post-HCT infectious episodes or intensive care unit admissions. Here we report significantly lower rates of chronic GVHD and significant improvement in GRFS in an ATG exposed MUD alloHCT cohort compared with an ATG unexposed MRD cohort. These findings were observed without differences in relapse, survival, infectious complications, or intensive care unit admissions. Our findings highlight the association of unconventionally low-dose ATG with improved GVHD outcomes and suggest a need for prospective study of ATG use in lower doses.
18
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
Philippe Armand, Haesook T. Kim, Brent R. Logan et al. · Blood · 2014 · 942 citations · Full text
Medicine, Hematology, Immunology +14
Jürgen Finke, Wolfgang Bethge, Claudia Schmoor et al. · The Lancet Oncology · 2009 · 719 citations
Irwin Walker, Tony Panzarella, Stephen Couban et al. · The Lancet Oncology · 2015 · 363 citations
Medicine, Hematology, Immunology +17
Andrea Bacigalupo, Teresa Lamparelli, Giovanni Barisione et al. · Biology of Blood and Marrow Transplantation · 2006 · 341 citations · Full text